Suppr超能文献

使用天花抗病毒药物tecovirimat(ST-246)单独治疗或与ACAM2000疫苗联合治疗,作为猴痘病毒感染的症状出现后疗法是有效的。

Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.

作者信息

Berhanu Aklile, Prigge Jonathan T, Silvera Peter M, Honeychurch Kady M, Hruby Dennis E, Grosenbach Douglas W

机构信息

SIGA Technologies, Inc., Corvallis, Oregon, USA

Southern Research Institute, Frederick, Maryland, USA.

出版信息

Antimicrob Agents Chemother. 2015 Jul;59(7):4296-300. doi: 10.1128/AAC.00208-15. Epub 2015 Apr 20.

Abstract

The therapeutic efficacies of smallpox vaccine ACAM2000 and antiviral tecovirimat given alone or in combination starting on day 3 postinfection were compared in a cynomolgus macaque model of lethal monkeypox virus infection. Postexposure administration of ACAM2000 alone did not provide any protection against severe monkeypox disease or mortality. In contrast, postexposure treatment with tecovirimat alone or in combination with ACAM2000 provided full protection. Additionally, tecovirimat treatment delayed until day 4, 5, or 6 postinfection was 83% (days 4 and 5) or 50% (day 6) effective.

摘要

在致死性猴痘病毒感染的食蟹猴模型中,比较了在感染后第3天开始单独或联合使用天花疫苗ACAM2000和抗病毒药物tecovirimat的治疗效果。单独暴露后给予ACAM2000不能提供针对严重猴痘疾病或死亡的任何保护。相比之下,单独或与ACAM2000联合使用tecovirimat进行暴露后治疗可提供完全保护。此外,将tecovirimat治疗延迟至感染后第4、5或6天,有效率分别为83%(第4天和第5天)或50%(第6天)。

相似文献

3
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.
Nature. 2006 Feb 9;439(7077):745-8. doi: 10.1038/nature04295. Epub 2005 Dec 11.
5
Treatment and Vaccination for Smallpox and Monkeypox.
Adv Exp Med Biol. 2024;1451:301-316. doi: 10.1007/978-3-031-57165-7_19.
6
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
Antimicrob Agents Chemother. 2009 May;53(5):1817-22. doi: 10.1128/AAC.01596-08. Epub 2009 Feb 17.
7
Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.
Antimicrob Agents Chemother. 2013 Mar;57(3):1136-43. doi: 10.1128/AAC.00959-12. Epub 2012 Dec 17.
8
New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0122622. doi: 10.1128/aac.01226-22. Epub 2022 Nov 14.
10
Oral Tecovirimat for the Treatment of Smallpox.
N Engl J Med. 2018 Jul 5;379(1):44-53. doi: 10.1056/NEJMoa1705688.

引用本文的文献

2
Uncovering the impact of infection routes on within-host MPXV dynamics: Insights from a mathematical modeling study.
PLoS Comput Biol. 2025 May 19;21(5):e1013073. doi: 10.1371/journal.pcbi.1013073. eCollection 2025 May.
3
Monkeypox: Prevention Strategies and Challenges: Updated Review.
Health Sci Rep. 2025 Apr 8;8(4):e70640. doi: 10.1002/hsr2.70640. eCollection 2025 Apr.
4
Clade IIb Mpox virus (MPXV) vertical transmission and fetal demise in a pregnant rhesus macaque model.
PLoS One. 2025 Apr 1;20(4):e0320671. doi: 10.1371/journal.pone.0320671. eCollection 2025.
5
Epidemiology, Pathogenesis, and Treatment Options of Monkeypox: A Narrative Review.
Cureus. 2025 Jan 23;17(1):e77892. doi: 10.7759/cureus.77892. eCollection 2025 Jan.
6
Mpox: Global epidemic situation and countermeasures.
Virulence. 2025 Dec;16(1):2457958. doi: 10.1080/21505594.2025.2457958. Epub 2025 Feb 8.
7
The resurgence of monkeypox: Epidemiology, clinical features, and public health implications in the post-smallpox eradication era.
New Microbes New Infect. 2024 Sep 24;62:101487. doi: 10.1016/j.nmni.2024.101487. eCollection 2024 Dec.
9
Molecular Virology of Orthopoxviruses with Special Reference to Monkeypox Virus.
Adv Exp Med Biol. 2024;1451:111-124. doi: 10.1007/978-3-031-57165-7_7.
10
Biological Characteristics and Pathogenesis of Monkeypox Virus: An Overview.
Adv Exp Med Biol. 2024;1451:91-109. doi: 10.1007/978-3-031-57165-7_6.

本文引用的文献

1
Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).
Antimicrob Agents Chemother. 2013 Dec;57(12):6246-53. doi: 10.1128/AAC.00977-13. Epub 2013 Oct 7.
4
Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.
Vaccine. 2010 Dec 16;29(2):289-303. doi: 10.1016/j.vaccine.2010.10.039. Epub 2010 Oct 29.
5
ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
Antimicrob Agents Chemother. 2009 Dec;53(12):4999-5009. doi: 10.1128/AAC.00678-09. Epub 2009 Sep 14.
6
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
Antimicrob Agents Chemother. 2009 May;53(5):1817-22. doi: 10.1128/AAC.01596-08. Epub 2009 Feb 17.
7
In vitro efficacy of ST246 against smallpox and monkeypox.
Antimicrob Agents Chemother. 2009 Mar;53(3):1007-12. doi: 10.1128/AAC.01044-08. Epub 2008 Dec 15.
8
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model.
Antiviral Res. 2008 Aug;79(2):121-7. doi: 10.1016/j.antiviral.2008.03.005. Epub 2008 Apr 23.
9
Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.
Vaccine. 2008 Feb 13;26(7):933-46. doi: 10.1016/j.vaccine.2007.11.095. Epub 2007 Dec 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验